VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$5.74Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $295,552,576.00
EPSttm : -3.66
Verastem, Inc.
$5.74
15.73%$0.78Float Short %
17.28
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
0.72
EPS Last/This Y
1.31
EPS This/Next Y
0.85
Price
5.74
Target Price
13
Analyst Recom
1
Performance Q
8.71
Relative Volume
1.34
Beta
0.96
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | VSTM | 6.82 | 0.18 | 0.00 | 5204 |
| 2025-03-21 | VSTM | 6.67 | 0.18 | 0.00 | 5323 |
| 2025-03-24 | VSTM | 6.87 | 0.23 | 0.00 | 2957 |
| 2025-03-25 | VSTM | 6.57 | 0.20 | 0.00 | 3339 |
| 2025-03-26 | VSTM | 6.38 | 0.19 | 0.00 | 3440 |
| 2025-03-27 | VSTM | 6.72 | 0.18 | 0.02 | 3634 |
| 2025-03-28 | VSTM | 6.17 | 0.18 | 0.00 | 3673 |
| 2025-03-31 | VSTM | 6.05 | 0.18 | 0.18 | 3685 |
| 2025-04-01 | VSTM | 5.82 | 0.17 | 0.31 | 3789 |
| 2025-04-02 | VSTM | 5.85 | 0.19 | 0.01 | 3916 |
| 2025-04-03 | VSTM | 5.72 | 0.19 | 5.67 | 3948 |
| 2025-04-04 | VSTM | 5.17 | 0.20 | 0.11 | 4005 |
| 2025-04-07 | VSTM | 5.1 | 0.20 | 0.10 | 3999 |
| 2025-04-08 | VSTM | 4.64 | 0.20 | 0.06 | 4031 |
| 2025-04-09 | VSTM | 5.29 | 0.17 | 0.03 | 4018 |
| 2025-04-10 | VSTM | 4.51 | 0.17 | 0.69 | 4019 |
| 2025-04-11 | VSTM | 4.64 | 0.18 | 0.00 | 4113 |
| 2025-04-14 | VSTM | 4.78 | 0.17 | 0.06 | 4147 |
| 2025-04-15 | VSTM | 4.82 | 0.14 | 0.00 | 4145 |
| 2025-04-16 | VSTM | 4.97 | 0.13 | 0.00 | 4336 |
| 2025-04-17 | VSTM | 5.72 | 0.12 | 0.02 | 4554 |
| 2025-04-18 | VSTM | 5.74 | 0.12 | 0.00 | 4554 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | VSTM | 6.82 | 33.0 | - | -2.98 |
| 2025-03-21 | VSTM | 6.66 | 33.0 | - | -2.98 |
| 2025-03-24 | VSTM | 6.88 | 37.8 | - | -2.98 |
| 2025-03-25 | VSTM | 6.57 | 37.8 | - | -2.98 |
| 2025-03-26 | VSTM | 6.40 | 37.8 | - | -2.98 |
| 2025-03-27 | VSTM | 6.73 | 37.8 | - | -2.98 |
| 2025-03-28 | VSTM | 6.19 | 37.8 | - | -2.35 |
| 2025-03-31 | VSTM | 6.03 | 37.8 | - | -2.35 |
| 2025-04-01 | VSTM | 5.82 | 37.8 | - | -2.35 |
| 2025-04-02 | VSTM | 5.84 | 37.8 | - | -2.35 |
| 2025-04-03 | VSTM | 5.70 | 37.8 | - | -2.35 |
| 2025-04-04 | VSTM | 5.16 | 37.8 | - | -2.35 |
| 2025-04-07 | VSTM | 5.10 | 37.8 | - | -2.35 |
| 2025-04-08 | VSTM | 4.64 | 37.8 | - | -2.35 |
| 2025-04-09 | VSTM | 5.28 | 37.8 | - | -2.35 |
| 2025-04-10 | VSTM | 4.51 | 37.8 | - | -2.35 |
| 2025-04-11 | VSTM | 4.64 | 37.8 | - | -2.35 |
| 2025-04-14 | VSTM | 4.78 | 37.8 | - | -2.35 |
| 2025-04-15 | VSTM | 4.81 | 37.8 | - | -2.35 |
| 2025-04-16 | VSTM | 4.97 | 37.8 | - | -2.35 |
| 2025-04-17 | VSTM | 5.74 | 37.8 | - | -2.35 |
| 2025-04-18 | VSTM | 5.74 | 37.8 | - | -2.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | VSTM | -0.28 | 31.62 | 15.11 |
| 2025-03-21 | VSTM | -0.26 | 31.62 | 15.11 |
| 2025-03-24 | VSTM | -0.23 | 26.21 | 15.11 |
| 2025-03-25 | VSTM | -0.23 | 26.21 | 15.11 |
| 2025-03-26 | VSTM | -0.23 | 26.21 | 16.03 |
| 2025-03-27 | VSTM | -0.23 | 26.21 | 16.03 |
| 2025-03-28 | VSTM | -0.23 | 26.21 | 16.03 |
| 2025-03-31 | VSTM | -0.23 | 51.96 | 16.03 |
| 2025-04-01 | VSTM | -0.23 | 51.96 | 16.03 |
| 2025-04-02 | VSTM | -0.23 | 51.96 | 16.03 |
| 2025-04-03 | VSTM | -0.23 | 51.96 | 16.03 |
| 2025-04-04 | VSTM | -0.23 | 51.96 | 16.03 |
| 2025-04-07 | VSTM | -0.23 | 52.00 | 16.05 |
| 2025-04-08 | VSTM | -0.23 | 52.00 | 16.05 |
| 2025-04-09 | VSTM | -0.23 | 52.00 | 16.05 |
| 2025-04-10 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-11 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-14 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-15 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-16 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-17 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-18 | VSTM | -0.23 | 52.00 | 17.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.33
Avg. EPS Est. Current Quarter
-0.61
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-0.23
Institutional Transactions
52
Beta
0.96
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
7
Growth Score
37
Sentiment Score
27
Actual DrawDown %
90.3
Max Drawdown 5-Year %
-96.2
Target Price
13
P/E
Forward P/E
PEG
P/S
29.55
P/B
P/Free Cash Flow
EPS
-3.49
Average EPS Est. Cur. Y
-2.35
EPS Next Y. (Est.)
-1.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1306.36
Relative Volume
1.34
Return on Equity vs Sector %
432.2
Return on Equity vs Industry %
445.5
EPS 1 7Days Diff
0.4
EPS 1 30Days Diff
0.45
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading